• Merck opened a bioprocessing production center in Daejeon, South Korea, representing an investment of more than €300 million.
• The company's largest life science investment in Asia-Pacific expands regional manufacturing capacity for materials used in biologic medicines.
• The facility is designed to eliminate on-site fossil fuel use while improving energy and water efficiency.
• Solar power, heat pumps and rainwater reuse support the site's environmental design.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290800PRIMZONEFULLFEED9856023) on October 29, 2026, and is solely responsible for the information contained therein.